Scholarlink

Purpose of Review <p>Adjuvant immunotherapy has improved outcomes in several cancers, although patient selection and toxicity remain challenges. Circulating tumor DNA (ctDNA) has emerged as a biomarker for minimal residual disease (MRD) detection, although its role in guiding adjuvant immunotherapy remains unproven. The aim of this review was to summarize the current evidence on ctDNA in the adjuvant immunotherapy setting of solid tumors.</p> Recent Findings <p>Data from various tumor types guiding ctDNA-driven treatment escalation or de-escalation in the context of adjuvant immunotherapy remain sparse, limited to small prospective trials, many of which have struggled with enrolment and yielded inconclusive results. Challenges include analytical and clinical validation, as well as the optimal treatment management of either ctDNA positive and negative patients, posing ethical challenges in designing clinical trials.</p> Summary <p>ctDNA has strong prognostic value in detecting MRD but is not validated for guiding adjuvant immunotherapy, and well-designed prospective trials are required to establish its role. Future research should focus on integrated models combining ctDNA with other biomarkers to improve sensitivity and specificity, while balancing cost-effectiveness and clinical feasibility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?

  • 期刊论文

  • 发表日期：

    2025年7月20日

查看全文
  • Michele Maffezzoli,
  • Ria Nagpal,
  • Mohamed Elewaily,
  • Lohitha Pedapati,
  • Justin Samuel,
  • Sebastiano Buti,
  • Umberto Malapelle,
  • Akash Maniam,
  • Giuseppe Luigi Banna

摘要

Purpose of Review

Adjuvant immunotherapy has improved outcomes in several cancers, although patient selection and toxicity remain challenges. Circulating tumor DNA (ctDNA) has emerged as a biomarker for minimal residual disease (MRD) detection, although its role in guiding adjuvant immunotherapy remains unproven. The aim of this review was to summarize the current evidence on ctDNA in the adjuvant immunotherapy setting of solid tumors.

Recent Findings

Data from various tumor types guiding ctDNA-driven treatment escalation or de-escalation in the context of adjuvant immunotherapy remain sparse, limited to small prospective trials, many of which have struggled with enrolment and yielded inconclusive results. Challenges include analytical and clinical validation, as well as the optimal treatment management of either ctDNA positive and negative patients, posing ethical challenges in designing clinical trials.

Summary

ctDNA has strong prognostic value in detecting MRD but is not validated for guiding adjuvant immunotherapy, and well-designed prospective trials are required to establish its role. Future research should focus on integrated models combining ctDNA with other biomarkers to improve sensitivity and specificity, while balancing cost-effectiveness and clinical feasibility.